Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
234 hedge funds and large institutions have $4.73B invested in Global Blood Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 77 increasing their positions, 62 reducing their positions, and 27 closing their positions.
172% more call options, than puts
Call options by funds: $174M | Put options by funds: $64M
130% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 27
63% more capital invested
Capital invested by funds: $2.91B → $4.73B (+$1.82B)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
24% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 62
13% more funds holding
Funds holding: 208 → 234 (+26)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$68.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$63.8M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$43.3M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$32.6M |
| 5 |
Millennium Management
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$53.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$51.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$50.7M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$48.5M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$24M |
GBT Hedge Fund Activity: Q4 2019 in Review
234 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2019, worth a combined $4.73B — up 63% from $2.91B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new GBT positions and 27 closed out — a net gain of 35 holders — while 77 added to existing stakes and 62 trimmed.
The largest buyer was Bank of America, adding an estimated $68.5M. The largest seller was Wellington Management Group, cutting an estimated $53.7M.
- 234 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2019, up from 208 in Q3 2019.
- Funds reported $4.73B of Global Blood Therapeutics, Inc. stock for Q4 2019, up 63% quarter-over-quarter.
- 62 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2019 and 27 closed out, a net change of +35 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q4 2019 was Bank of America, an estimated $68.5M added.
- The largest Global Blood Therapeutics, Inc. seller in Q4 2019 was Wellington Management Group, an estimated $53.7M sold.
Based on aggregated 13F filings for Q4 2019.